Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses
Listen to this summary
This study investigates how the number and timing of primary doses of the 20-valent pneumococcal conjugate vaccine (PCV20) affect immune responses in infants. The analysis reveals that a 1-month delay in the priming doses from 2 and 4 months to 3 and 5 months results in stronger immune responses, comparable to those elicited by the 13-valent vaccine (PCV13). Overall, PCV20 was found to be safe and well tolerated across different dosing schedules.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from The Pediatric infectious disease journal
View all →More in Pediatrics
View all →Aug 7, 2026 · European heart journal
Temporal comparison of clinical practice and outcomes in heart failure: the JROADHF and JROADHF-NEXT studies
Aug 7, 2026 · Critical care medicine
Geographic Access to Care and Mortality in Cardiogenic Shock: A Nationwide Cohort Analysis
Aug 7, 2026 · Pediatric nephrology (Berlin, Germany)
Anti-rituximab antibodies: implications for clinical outcomes and safety in pediatric idiopathic nephrotic syndrome
Aug 7, 2026 · Critical care medicine
Rethinking Muscle Wasting in Critical Illness: A Systematic Review and Meta-Analysis of Myofiber Size and Protein Turnover
Aug 7, 2026 · Critical care medicine
Telemedicine Critical Care Billing For Hospitalized Medicare Fee-For-Service Beneficiaries, 2018-2024
Aug 7, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


